07/02/2022

ESTEVE APPOINTS JOSÉ MARÍA GIMÉNEZ ARNAU AS CHIEF SCIENTIFIC & MEDICAL OFFICER

Since 1 February, Giménez Arnau has joined the company as a member of the Executive Management, reporting to Staffan Schüberg, Chief Executive Officer of ESTEVE.

ESTEVE has announced the appointment of José María Giménez Arnau as its new Chief Scientific & Medical Officer. Since 1 February, Giménez Arnau has joined the company as a member of the Executive Management, reporting to Staffan Schüberg, Chief Executive Officer of ESTEVE.

José María Giménez Arnau is taking over from Carlos Plata, who is stepping down from his responsibilities as head of the scientific and medical area. Giménez Arnau has a degree in Medicine and Surgery from the University of Barcelona, specializing in Occupational Medicine and Diseases. He holds a master’s degree in Pharmaceutical Medicine from UAB and a PDD (Management Development Program) from IESE. He has more than 30 years' experience in the pharmaceutical industry where he has held various positions in the Medical Affairs, Clinical Development and Commercial areas, both at a local and global level, in such pharmaceutical companies as Menarini, Prasfarma, ASTA Medica, Amgen and Novartis. Throughout his career, he has accumulated extensive experience including running several global clinical development programs and filing international regulatory submissions gaining an extensive knowledge of all aspects of clinical and regulatory development in the global setting.

Prior to joining ESTEVE, he held the position of VP Global Clinical Development & Analytics Strategic Projects at Novartis Pharmaceuticals AG in Basel

Staffan Schüberg, Chief Executive Officer of ESTEVE, has stated that "José Maria’s extensive experience in the sector will help us to achieve our goal of being a leading proprietary company in specialized medicine". With regard to Carlos Plata he highlights "Carlos will continue to collaborate with the company as an external advisor and we would also like to thank him for his contributions and his excellent work at the head of ESTEVE’s scientific and medical teams".

For his part, José María Giménez Arnau has also said "I am thrilled to take this step in my career and become part of this important and ambitious project in a benchmark company such as ESTEVE. I am fully committed to ESTEVE’s main strategic role in becoming an international specialized pharmaceutical company in benefit for patients all over the world".